The Japanese anticancer drug market is in the same situation as Korea, where anticancer drugs are administered in hospitals, but Japan uses CSTD, which offsets negative pressure, which is not adopted in Korea, as insurance for about 20,000 won, and We found that robots are used in very few hospitals the same as Korea.

In BSC, humans (pharmacists or dispensing experts) are dispensing with syringes as in Korea, so they are exposed to the highly toxic anticancer oil vapor due to negative pressure and air removal in the syringe, which is the most avoided task, and high wages are accompanied.

Like Korea, Robots are employed in fewer hospitals than in Korea because of their limited dispensing volume, low dispensing rate, and high price.

We are in progress for signing confidentiality agreements with two companies for consulting on ACPi Anyfusion v100 (manual), ACPi Anyfusion Pro (semi-automatic), and AACPi Anyfusion Pro (automatic), including Japanese Food and Drug Administration (PMDA) certification, clinical, and market research, and signed an agreement.

In the same situation in the US, Japan, and Germany, we are going to promote the rapid marketization of ACPi and Anyfusion as the Anyfusion Platform business that fits the local situation.

Thank you.